In recent decades, identification of the dopaminergic deficit in Parkinson's disease has spawned an explo sion of research in the molecular neurobiology of the basal ganglia. In vivo imaging has provided a tool to bridge developments in basic neuroscience and clinicial neurology. Imaging studies have opened a unique window on the neurochemical pathophysiology of Parkinson's disease and more specifically on the onset, progression and physiology of the degenerative process. As we are poised on the brink of new protective and restorative therapies for Parkinson's disease, the potential of imaging to teach us about in vivo brain neurochemistry offers both promise and challenge. NEUROSCIENTIST 5:333-340, 1999
Parkmson J.An essay on the shaking palsyLondon: Sherwood, Neely, and Jones; 1819.
2.
Bernheimer H. , Birkmayer W., Hornykiewicz O., Jellinger K., Seitleberger F.Brain dopamine and the syndromes of Parkmson and Huntington, clinical, morphological, and neurochemical correlatesJ Neurol Sci1973 ;20:415-455.
3.
Calne DBIs idiopathic Parkinsonism the consequence of an event or a process?Neurology1993;44:5-10.
4.
Langston J., Koller W.The next frontier in Parkinson's disease: presymptomatic detectionNeurology1991;41:5-7.
5.
Duvoisin R.The genetics of Parkinson's diseaseAdv Neurol1993;60:306-315.
6.
Wichman T., Vitek J., DeLong M.Parkinson's disease and the basal ganglia: lessons from the laboratory and from neurosurgeryTHE NEUROSCIENTIST1995 ;1:236-244.
7.
Kish SJ, Shannak K., Hornykiewicz O.Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's diseaseN Engl J Med1988;318:876-880.
McGeer PL, Itagaki S., Akiyama S., McGeer EGRate of cell death in Parkinsonism is an active neuropathological processAnn Neurol1988;24:574.
10.
Martilla R. , Rinne U.Epidemiology of Parkinson's disease in FinlandActa Neurol Scand1967;43:9-61.
11.
Rajput A., Offord K., Beard C., Kurland L.Epidemiology of Parkinson's disease. Incidence, classification and mortalityAnn Neurol1984:278:278-87.
12.
Tanner C.Epidemiologic clues to the cause of Parkinson's disease In: Fahn S, Marsden CD, editors. Movement disorders 3. Oxford: Butterworth-Heinemann; 1994 . p. 124-146.
13.
Hoehn M., Yahr MDParkinsonism: onset, progression and mortalityNeurology1967;17-427-442.
14.
Calne D.Treatment of Parkinson's diseaseN Engl J Med1993; 329:1021-1027.
15.
Koller W., Silver D., Lieberman A.An algorithm for managing Parkinson's diseaseNeurology1994;44:S1-S52.
16.
Olanow C.Attempts to obtain neuroprotection m Parkinson's diseaseNeurology1997,S26-S33.
17.
Ogawa N.Possible neuroprotective therapy for Parkinson's disease. Acta Med Okayama1995;49179-185.
18.
Freese A., Stem M., Kaplitt M., O'Connor WM, Abbey MV, O'Connor MJ, et al.Prospects for gene therapy in Parkinson's diseaseMov Disord1996;11:469-488.
19.
Phelps M.Positron emission tomography (PET In. Mazziota JC, Gilman S, editors. Clinical brain imaging: principles and applications.Philadelphia: FA Davis; 1992. p 71-107.
20.
Lassen N., Holm S.Single photon emission computerized tomography (SPECT In: Mazziota JC, Gilman S, editors. Clinical brain imaging: principles and applications.Philadelphia: FA Davis; 1992. p. 108-134.
21.
Friston K., Frith C., Liddle P., Dolan R., Lammertsma A., Frackowiak R.The relationship between global and local changes in PET scansJ Cereb Blood Flow Metab1990;10:458-466.
22.
Brooks DJFunctional imaging in relation to Parkinsonian syndromesJ Neurol Sci1993;115:1-17.
23.
Calne DB, Langston JW, Martin Wrw, Stoessl AJ, Ruth TJ, Adam MJ, et al.Positron emission tomography after MPTP: observations relating to the cause of Parkinson's diseaseNature1985;317:246-248.
24.
Leenders K. , Salmon EP, Tyrrell P., Perani D., Brooks DJ, Sager H., et al.The nigrostnatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's diseaseArch Neurol1990;47:1290-1298.
25.
Nahmias C., Garnett ES, Firnau G., Lang A.Stnatal dopamme distribution in Parkinsonian patients during lifeJ Neurol Sci1985; 69:223-230.
26.
Fischman A. , Bonab A., Babich J., Alpert NM, Elmaleh DR, Barrow SA, et al.SPECT imaging of the dopamine transporter with [123I]-2β-carbomethoxy-3β-(4-fluorophenyl)-N-(1-iodoprop-1-en-3-yl) nortropane ([123I]IACFT): initial expenence in humansNeuroscience-Net [serial online]1996;1(#00010):[28 screens]. Available from: URL: http://www.neuroscience.com/iacft/htm/mdex.html .
27.
Booij T., Tissmgh G., Boer G.[123I]FP-SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's diseaseJ Neurol Neurosurg Psychiatry1997; 62:133-140.
28.
Frost JJ, Rosier AJ, Reich SG, et al.Positron emission tomography imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked decline in mild Parkinson's diseaseAnn Neurol1993:34:423-31.
29.
Innis RB, Seibyl JP, Scanley BE, Laruelle M., Abi-Dargham A., Wallace E., et al.Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkmson diseaseProc Natl Acad Sci U S A1993;90:11965-11969.
30.
Tatsch K., Schwarz J., Mozley PD, Linke R., Pogarell O., Oertel WH, et al.Relationship between clinical features of Parkmson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomographyEur J Nucl Med1997;24:415-421.
31.
Seibyl J., Marek K., Qumlan D., Sheff K., Zoghbi S., Zea-Ponce Y., et al.Decreased SPECT [123I]b-CIT striatal uptake correlates with symptom severity in idiopathic Parkmson's diseaseAnn Neurol1995;38:589-598.
32.
Brücke T., Asenbaum S., Pirker W., Djamshidian S., Wenger S., Wober CH, et al.Measurement of the dopaminergic degeneration in Parkinson's disease with [123I]b-CIT and SPECTJ Neural Transm1997;50 Suppl:9-24.
33.
Brooks D., Ibanez V., Sawle G., Playford ED, Quinn N., Mathias CJ, et al.Striatal D2 Receptor Status in Patients with Parkmson's Disease, Striatonigral Degeneration, and Progressive Supranuclear Palsy, Measured with 11C-Raclopride and Positron Emission TomographyAnn Neurol1992;31:184-192.
34.
Tatsch K., Schwarz J., Oertel W., Kirsch C.Dopamine D2 receptor imaging with I-123 IBZM SPECT to differentiate idiopathic from other Parkmson syndromesJ Nucl Med1992;33:917-918.
35.
Antonini A. , Schwarz J., Oertel W., Beer H., Madejo U., Leenders K.[11C]raclopride and positron emission tomography m previously untreated patients with Parkinson's disease: influence of L-dopa and lisuride therapy on striatal dopamine D2-receptorsNeurology1994;44:1325-1329.
36.
Hughes AJ, Daniel SE, Kilford L., Lees AJAccuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 casesJ Neurol Neurosurg Psychiatry1992;55:1142-1146.
37.
Rajput A.Rodzilsky B., Rajput A.Accuracy of clinical diagnosis of Parkinsonism—a prospective studyCan J Neurol Sci1991;18: 275-278.
38.
Morrish P., Sawle G., Brooks D.Clinical and [18F]dopa PET findmgs in early Parkmson's diseaseJ Neurol Neurosurg Psychiatry1995 ;59:597-600.
39.
Marek K., Seibyl J., Scanley B., Zea-Ponce Y., Baldwm RM, Fussell B., et al.[123I]βCIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's diseaseNeurology1996;46:231-237.
40.
Guttman M., Burkholder J., Kish S., Hussey D., Wilson A., DaSilva J., et al.[11C] RTI-32 PET studies of the dopamme transporter m early dopa-naive Parkinson's diseaseNeurology1997;48.1578-1583.
41.
Sawle G., Playford E., Burn D., Cunnigham V., Brooks D.Separatmg Parkinson's disease from normality: discriminant function analysis of [18F]dopa PET dataArch Neurol1994;51:237-243.
42.
Eidelberg D. , Moeller J., Ishikawa M., Dhawan V., Spetsieris P., Chaly T., et al.Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomographyNeurology1995 ;45:1995-2004.
43.
Snow B., Tooyama I., McGeer E., Calne D.Human positron emission tomographic [18F]fluorodopa studies correlate with dopamme cell counts and levelsAnn Neurol1993;34:324-330.
44.
Litvan I., Agid Y., Calne D., Campbell G., Dubois B., Duvoisin RC, et al.Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndromeNeurology1996;47:1-9.
45.
Wennmg G., Tison F., Shlomo B., Daniel S., Quinn N.Multiple system atrophy: a review of 203 pathologically proven casesMovement Disorders1997;12:133-46.
46.
Brooks D., Ibanez V., Sawle G., Quinn N., Lees AJ, Mathias CJ, et al.Differing patterns of striatal 18F-DOPA uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsyAnn Neurol1990;28:547-555.
47.
Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkmson Study GroupN Engl J Med1993;328:176-183.
48.
Effect of deprenyl on the progression of disability m early Parkinson's disease. Parkinson Study GroupN Engl J Med1989;21:1364-1371.
49.
Vmgerhoets Fjg, Snow BJ, Lee CS, Schulzer M., Mak E., Calne DBLongitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic ParkinsonismAnn Neurol1994;36:759-64.
50.
Momsh P., Sawle G., Brooks D.An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's diseaseBrain1996;119:585-591.
51.
Schwarz J., Tatsch, K., Linker R., Pogarell O., Mozley D., Kung H.Measuring the decline of dopamine transporter binding in patients with Parkinson's disease using 123I-IPT and SPECTNeurology1997;48:A208.
52.
Marek K., Seibyl J.Fussell B., Cellar J., Smith E., Innis RB[123I]b-CIT: assessment of progression in Parkinson's diseaseNeurology1997;48:A207.
53.
Sawle G., Myers R.The role of positron emission tomography in the assessment of human transplantationTrends Neurosci1993; 16:260-264.
54.
Tomac A., Lindqvist E., Lm L-F., et al.Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivoNature1995; 373:335-339.
55.
Olanow C., Kordower J., Freeman T.Fetal nigral transplantation as a therapy for Parkinson's diseaseTrends Neurosci1996;19:102-109.
56.
van Dyck C. , Seibyl J., Malison R., Laruelle M., Wallace E., Zoghbi SS, et al.Age-related decline in dopamine transporter binding in human striatum with [123 I]b-CIT SPECTJ Nucl Med1995;36: 1175-1181.
57.
Sawle GV, Colebatch JG, Shah A., Brooks DJ, Marsden CD, Frackowiak Rjs.Stnatal function m normal aging-implications for Parkinson's diseaseAnn Neurol1990;28:799-804.
58.
Piccini P., Momsh P., Turjanski N., Sawle GV, Burn DJ, Weeks RA, et al.Dopaminergic function m familial Parkinson's disease: a clinical and 18F-Dopa positron emission tomography studyAnn Neurol1997;41:222-229.
59.
Burn DJ, Mark MH, Playford ED, Maraganore DM, Zimmerman TR Jr, Duvoisin RC, et al.Parkinson's disease in twins studied with 18F-DOPA and positron emission tomographyNeurology1992;42:1894-1900.
60.
Snow BJ, Peppard RF, Guttman M., Calne DBPositron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in Lytico-BodigArch Neurol1990;47:870-874.
61.
Golbe L.The genetics of Parkinson's disease: a reconsiderationNeurology1990;40:7-16.
62.
Polymeropoulos M., Higgins J., Golbe L., Johnson WG, Ide SE, Di Iorio G., et al.Mapping of a gene for Parkinson's disease to chromosome 4q21-q12Science1996 ;1197-1199.
